Sanofi Gains EU Approval for Cenrifki as First Disability-Targeting Therapy in Non-Relapsing SPMS

The European Commission's approval of Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis sets a new pharmacovigilance and manufacturing quality benchmark for first-in-class CNS therapies in the EU, one that QA directors and regulatory affairs leads will need to map against existing infrastructure before commercial supply begins. Sanofi confirmed the decision on 23 June 2026, following a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).

Cenrifki is the first approved therapy specifically targeting disability progression in patients with SPMS who have had no clinical relapses in the preceding 24 months. The approval rests primarily on the HERCULES phase 3 study (NCT04411641), a double-blind, randomised trial in nrSPMS that used six-month confirmed disability progression as its primary endpoint, with supporting efficacy data drawn from the GEMINI 1 and GEMINI 2 relapsing MS studies.

The safety profile carries a defined liability that will drive post-approval compliance workload. Drug-induced liver injury (DILI) is an identified risk; significant liver enzyme elevations were observed across the clinical programme. Sanofi's approval package includes mandatory liver enzyme monitoring requirements and a Risk Management Program (RMP), obligations that will require pharmacovigilance teams to establish signal-detection workflows and patient-level monitoring protocols before any commercial dispensing occurs.

The phased commercial launch adds a supply-chain dimension. Sanofi has confirmed Germany as the first market, with availability planned for later in 2026 in close coordination with local MS specialists and a structured Patient Support Program. For manufacturing and distribution teams, that sequencing means GMP-compliant batch release, serialisation, and cold-chain documentation must be aligned to a single-market rollout before broader EU supply scales. Regulatory affairs leads in other EU member states should anticipate national pricing and reimbursement timelines that will lag the German entry point.

For QA and regulatory functions, the Cenrifki approval is a reference case: a first-in-class CNS agent cleared under a mandatory RMP, with hepatotoxicity monitoring baked into the label, launching in a staged geographic sequence. Each of those elements carries its own documentation and deviation-management implications under ICH Q10 and applicable 21 CFR Part 211 equivalents for EU-facing operations.

The six-month confirmed disability progression endpoint used in HERCULES is now on record as an EMA-accepted primary measure for nrSPMS trials, a data point that will inform protocol design for any competitor programmes targeting the same population.

Source: Sanofi via GlobeNewswire, 23 June 2026.